Imugene Limited (AU:IMU) has released an update.
Imugene Limited has commenced enrolment for an expansion study targeting bile tract cancer after positive preliminary results from their MAST trial, particularly in patients with cholangiocarcinoma. One patient achieved a complete response and another stable disease with the company’s CF33-hNIS (VAXINIA) virus. Additionally, the FDA has granted Fast Track Designation for VAXINIA, expediting the development and review process for this promising treatment option.
For further insights into AU:IMU stock, check out TipRanks’ Stock Analysis page.
